Present and future of cancer biomarkers

Clinical Chemistry and Laboratory Medicine

Volumn 52, Issue 6, 2014, Pages 791-794

  Diamandis, Eleftherios P ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Cancer biomarkers; Mass spectrometry; Mutant proteins; P53 gene mutations; Whole genome sequencing

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; MUTANT PROTEIN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

BODY FLUID; BREAST CANCER; CANCER PROGNOSIS; CANCER SCREENING; CLINICAL PRACTICE; DIGESTIVE SYSTEM CANCER; EXOME; GENE; GENE SEQUENCE; GENOME; GENOMICS; HUMAN; LUNG CANCER; MASS SPECTROMETRY; MONITORING; MUTATION; NEOPLASM; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; METABOLISM;

HUMANS; NEOPLASMS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 84903582032     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2014-0317     Document Type: Review

References (16)

1. Diamandis EP, Hoffman BR, Sturgeon CM. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for the use of tumor markers. Clin Chem 2008;54:1935-9
2. Kulasingam V, Pavlou MP, Diamandis EP. Integrating highthroughput technologies in the quest for effective biomarkers for ovarian cancer. Nat Rev Cancer 2010;10:371-8
3. Diamandis EP. Cancer biomarkers: can we turn recent failures into success? J Natl Cancer Inst 2010;102:1462-7
4. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 2004;96:353-6 (Pubitemid 38351297)
5. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014;505:495-501
6. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature 2013;502:333-9
7. Ashworth A, Hudson TJ. Genomics: comparisons across cancers. Nature 2013;502:306-7
8. Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C. Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med 2012;4:127
9. McCluggage WG. Morphological subtypes of ovarian carcinoma: A review with emphasis on new developments and pathogenesis. Pathology 2011;43:420-32
10. Diamandis EP. A repository for "rare" tumor markers? Clin Chem Lab Med 2014;52:795-7
11. Kinde I, Bettegowda C, Wang Y, Wu J, Agrawal N, Shih Ie, et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med 2013;5:167ra4
12. Drabovich AP, Dimitromanolakis A, Saraon P, Soosaipillai A, Batruch I, Mullen B, et al. Differential diagnosis of azoospermia with proteomic biomarkers ECM1 and TEX101 quantified in seminal plasma. Sci Transl Med 2013;5:212ra160
13. Diamandis EP, Bast RC Jr, Gold P, Chu TM, Magnani JL. Reflection on the discovery of carcinoembryonic antigen, prostate-specific antigen, and cancer antigens CA125 and CA19-9. Clin Chem 2013;59:22-31
14. Rittenhouse H, Blase A, Shamel B, Schalken J, Groskopf J. The long and winding road to FDA approval of a novel prostate cancer test: our story. Clin Chem 2013;59:32-4
15. Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, et al. Multitarget stool DNA testing for colorectalcancer screening. N Engl J Med. doi: 10.1056/NEJMoa1311194. [Epub ahead of print 19 Mar 2014]
16. Pavlou MP, Diamandis EP, Blasutig IM. The long journey of cancer biomarkers from the bench to the clinic. Clin Chem 2013;59:147-57.